Literature DB >> 29924445

Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant.

Farzad Khademi1,2, Amirhossein Sahebkar3,4,5, Mahdi Fasihi-Ramandi6, Ramezan Ali Taheri2.   

Abstract

A promising strategy for preventing illness and death caused by Mycobacterium tuberculosis (Mtb) is vaccination. In this study, we aimed to evaluate the capacity of a multicomponent vaccine comprising HspX/EsxS-fused protein, PLGA (poly (lactide-co-glycolide)) and DOTAP (1, 2-dioleoyl-3-trimethylammonium propane) in eliciting immune responses against Mtb in BALB/c mice. A preparation of PLGA nanoparticles (NPs) containing fused protein and DOTAP adjuvant was made using double emulsion solvent evaporation (w/o/w) and lipid film hydration methods, respectively. After three subcutaneous immunization of BALB/c mice with various formulations, ELISA technique was used to measure interferon-γ (IFN-γ) and interleukin-4 (IL-4) cytokines levels in splenocytes as well as serum anti-HspX/EsxS IgG1 and IgG2a titers. The results of the current study showed that PLGA/HspX/EsxS/DOTAP formulation was able to induce higher levels of FN-γ, IgG1, and IgG2a responses compared with BCG as the positive control, HspX/EsxS, HspX/EsxS/DOTAP and PLGA/HspX/EsxS formulations. Our results suggest that PLGA NPs, as delivery system, and DOTAP, as adjuvant, have a good potential to enhance immune responses against HspX/EsxS antigen after subcutaneous immunization of BALB/c mice.
© 2018 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Mycobacterium tuberculosiszzm321990; DOTAP; HspX/EsxS; PLGA; immune responses

Mesh:

Substances:

Year:  2018        PMID: 29924445     DOI: 10.1111/apm.12851

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  3 in total

1.  Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration.

Authors:  Farzad Khademi; Arshid Yousefi; Mohammad Derakhshan; Adel Najafi; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2019-08       Impact factor: 2.699

Review 2.  Therapeutic lipid-coated hybrid nanoparticles against bacterial infections.

Authors:  Lai Jiang; Hiang Wee Lee; Say Chye Joachim Loo
Journal:  RSC Adv       Date:  2020-02-27       Impact factor: 4.036

Review 3.  An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.

Authors:  Kailash C Petkar; Suyash M Patil; Sandip S Chavhan; Kan Kaneko; Krutika K Sawant; Nitesh K Kunda; Imran Y Saleem
Journal:  Pharmaceutics       Date:  2021-03-27       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.